Twelve-Month Contraceptive Supply Policies and Medicaid Contraceptive Dispensing.


Journal

JAMA health forum
ISSN: 2689-0186
Titre abrégé: JAMA Health Forum
Pays: United States
ID NLM: 101769500

Informations de publication

Date de publication:
02 Aug 2024
Historique:
medline: 31 8 2024
pubmed: 31 8 2024
entrez: 30 8 2024
Statut: epublish

Résumé

Nineteen states have passed legislation requiring insurers to cover the dispensation of a 12-month supply of short-acting, hormonal contraception. To determine whether 12-month contraceptive supply policies were associated with an increase in the receipt of 12-month or longer supply of contraception. This retrospective cohort study included data from all female Medicaid enrollees aged 18 to 44 years who used short-acting hormonal contraception (ie, pill, patch, or ring) from 2016 to 2020. Eleven treatment states where legislation required insurers to cover a 12-month supply of contraception to continuing users and 25 comparison states without such legislation prior to December 2020. Proportion of contraception months received via a single 12-month or longer fill. This study included 48 255 512 months of dispensed oral pill, patch, and ring contraception prescription supply among 4 778 264 female Medicaid enrollees. The majority of months of supplied contraception were for the contraceptive pill rather than the patch or ring. In a staggered difference-in-differences model, the 12-month supply policy was associated with an estimated 4.39-percentage point (pp) increase (95% CI, 4.38 pp-4.40 pp) in the proportion of contraception dispensed as part of a 12-month or longer supply, from a mean of 0.11% in treatment states during the first quarter of the study period. Investigating the heterogeneity in policy association across states, California stood out with a 7.17-pp increase (95% CI, 7.15 pp-7.19 pp) in the proportion of contraception dispensed as a 12-month or longer supply; in the other 10 treatment states, the policy association was less than 1 pp. In this cohort study of Medicaid recipients using short-acting hormonal contraception, the passage of a 12-month contraceptive supply policy was associated with a minimal increase in the proportion of contraception dispensed through a 12-month or longer supply.

Identifiants

pubmed: 39212977
pii: 2822787
doi: 10.1001/jamahealthforum.2024.2755
pmc: PMC11364992
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e242755

Références

BMC Womens Health. 2022 Jul 10;22(1):287
pubmed: 35820853
Obstet Gynecol. 2011 Mar;117(3):566-572
pubmed: 21343759
Obstet Gynecol. 2022 Mar 1;139(3):455-457
pubmed: 35115432
JAMA Health Forum. 2022 Feb 18;3(2):e215146
pubmed: 35977278
Contraception. 2009 May;79(5):369-74
pubmed: 19341849
Obstet Gynecol. 2006 Nov;108(5):1107-14
pubmed: 17077231
Contraception. 2019 Nov;100(5):367-373
pubmed: 31376381
Health Serv Res. 2023 Apr;58(2):498-507
pubmed: 36414429
J Am Pharm Assoc (2003). 2022 Jul-Aug;62(4):1296-1303.e2
pubmed: 35307310
Obstet Gynecol. 2011 Sep;118(3):615-622
pubmed: 21860291
JAMA Intern Med. 2019 Sep 01;179(9):1201-1208
pubmed: 31282923

Auteurs

Maria I Rodriguez (MI)

Center for Reproductive Health Equity, Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland.

Thomas H A Meath (THA)

Center for Health Systems Effectiveness, Oregon Health & Science University, Portland.

Ashley Daly (A)

Center for Health Systems Effectiveness, Oregon Health & Science University, Portland.

Kelsey Watson (K)

Center for Health Systems Effectiveness, Oregon Health & Science University, Portland.

K John McConnell (KJ)

Center for Health Systems Effectiveness, Oregon Health & Science University, Portland.

Hyunjee Kim (H)

Center for Health Systems Effectiveness, Oregon Health & Science University, Portland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH